Clinical Trials Logo

Recurrent WHO Grade III Glioma clinical trials

View clinical trials related to Recurrent WHO Grade III Glioma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04044937 Completed - Clinical trials for Recurrent Glioblastoma

Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms

UC-GlioFET
Start date: October 29, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize the grade of glial neoplasms. Imaging agents such as FET can help oncologist to see the tumor better during a positron emission tomography (PET) scan.

NCT ID: NCT03914742 Completed - Clinical trials for Recurrent Glioblastoma

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Start date: January 3, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating patients with recurrent gliomas.